What would a population-level approach to dementia risk reduction look like, and how would it work?


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
07 2023
Historique:
revised: 13 01 2023
received: 07 11 2022
accepted: 15 01 2023
medline: 27 7 2023
pubmed: 16 2 2023
entrez: 15 2 2023
Statut: ppublish

Résumé

Dementia is a leading global public health challenge. Prevention approaches have traditionally focused on individual-level strategies. However, such approaches have limited potential, particularly for resource-constrained populations in which exposure to risk factors is greatest, and exposure to protective factors is lowest. A population-level approach to dementia risk reduction is therefore essential to meet the scale of the challenge and to tackle global inequalities in risk and incidence of disease. Such approaches can be highly cost effective. In this viewpoint article, we describe what such an approach should look like, barriers and facilitators to success, and how we should go about achieving it. We include 10 strategic goals to achieve population-level dementia risk reduction and protection enhancement, targeted at researchers, professionals, funders, science communicators, governments, businesses, and policy makers. If we are to significantly reduce the prevalence of dementia there must be increased emphasis on population-level approaches. HIGHLIGHTS: Dementia risk reduction is a global public health priority Population-level approaches change societal conditions to make them less conducive to dementia's modifiable risk factors, and increase exposure to protective factors. Urgent development of population-level approaches is required to reduce the prevalence of, and inequalities in, dementia Action is required from researchers, governments and business, funders, public health professionals, and science communicators.

Identifiants

pubmed: 36791256
doi: 10.1002/alz.12985
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3203-3209

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Références

Prince M. World Alzheimer Report 2015: The Global Impact of Dementia | Alzheimer's Disease International. World Alzheimer's Report. 2015.
Walsh S, King E, Brayne C. France removes state funding for dementia drugs. BMJ. 2019;367:l6930. doi: 10.1136/bmj.l6930
Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;2006(1):CD001747. doi: 10.1002/14651858.CD001747.pub3
Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015(9):CD001191. doi: 10.1002/14651858.CD001191.pub4
Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3
McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;2019(3):CD003154. doi: 10.1002/14651858.CD003154.pub6
Ackley SF, Zimmerman SC, Brenowitz WD, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021;372:n156. doi: 10.1136/bmj.n156
Richard E, den Brok MGHE, van Gool WA. Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease. Alzheimers Dement. 2021;17(6):1051-1055. doi: 10.1002/alz.12379
Walsh S, Merrick R, Richard E, Nurock S, Brayne C. Lecanemab for Alzheimer's disease. BMJ. 2022;379:o3010. doi: 10.1136/bmj.o3010
Shaw AR, Perales-Puchalt J, Johnson E, et al. Representation of racial and ethnic minority populations in dementia prevention trials: a systematic review. J Prev Alzheimers Dis. 2022;9(1):113-118. doi: 10.14283/jpad.2021.49
Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013;382(9902):1405-1412. doi: 10.1016/S0140-6736(13)61570-6
Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological pathology of dementia: attributable-risks at death in the medical research council cognitive function and ageing study. PLoS Med. 2009;6(11):e1000180. doi: 10.1371/journal.pmed.1000180
Wolters FJ, Chibnik LB, Waziry R, et al. Twenty-seven-year time trends in dementia incidence in Europe and the United States: the Alzheimer Cohorts Consortium. Neurology. 2020;95(5):e519-e531. doi: 10.1212/WNL.0000000000010022
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi: 10.1016/S0140-6736(20)30367-6
Walsh S, Govia I, Wallace L, et al. A whole-population approach is required for dementia risk reduction. Lancet Healthy Longev. 2022;3(1):e6-e8.
Marteau TM, Rutter H, Marmot M. Changing behaviour: an essential component of tackling health inequalities. BMJ. 2021;372:n332.
Lykke M, Helbech B, Glümer C. Temporal changes in the attitude towards smoking bans in public arenas among adults in the Capital Region of Denmark from 2007 to 2010. Scand J Public Health. 2014;42(5):401-408. doi: 10.1177/1403494814529034
Platt S, Amos A, Godfrey C, Martin C, Ritchie D, White M. Evaluation of Smokefree England: A Longitudinal, Qualitative Study Project Final Report; 2009. www.york.ac.uk/phrc
Pell D, Mytton O, Penney TL, et al. Changes in soft drinks purchased by British households associated with the UK soft drinks industry levy: controlled interrupted time series analysis. The BMJ. 2021;372:n254. doi: 10.1136/bmj.n254
Yau A, Berger N, Law C, et al. Changes in household food and drink purchases following restrictions on the advertisement of high fat, salt, and sugar products across the Transport for London network: a controlled interrupted time series analysis. PLoS Med. 2022;19(2):e1003915. doi: 10.1371/journal.pmed.1003915
Brown H, Xiang H, Albani V, et al. No new fast-food outlets allowed! Evaluating the effect of planning policy on the local food environment in the North East of England. Soc Sci Med. 2022;306:115126. doi: 10.1016/j.socscimed.2022.115126
Dahlgren G, Whitehead M. The Dahlgren-Whitehead model of health determinants: 30 years on and still chasing rainbows. Public Health. 2021;199:20-24.
Diderichsen F, Andersen I, Manuel C, et al. Health Inequality-determinants and policies. Scand J Public Health. 2012;40(suppl 8):12-105.
Hafdi M, Hoevenaar-Blom MP, Richard E. Multi-domain interventions for the prevention of dementia and cognitive decline. Cochrane Database Syst Rev. 2021;11(11):CD013572. doi: 10.1002/14651858.CD013572.pub2
Rutter H, Savona N, Glonti K, et al. The need for a complex systems model of evidence for public health. Lancet. 2017;390(10112):2602-2604. doi: 10.1016/S0140-6736(17)31267-9
Hollands GJ, French DP, Griffin SJ, et al. The impact of communicating genetic risks of disease on riskreducing health behaviour: systematic review with meta-analysis. BMJ (Online). 2016;352:i1102. doi: 10.1136/bmj.i1102
Adams J, Mytton O, White M, Monsivais P. Why are some population interventions for diet and obesity more equitable and effective than others? The role of individual agency. PLoS Med. 2016;13(4):e1001990. doi: 10.1371/journal.pmed.1001990
Beason-Held LL, Goh JO, An Y, et al. Changes in brain function occur years before the onset of cognitive impairment. J Neurosci. 2013;33(46):18008-18014. doi: 10.1523/JNEUROSCI.1402-13.2013
Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804. doi: 10.1056/nejmoa1202753
Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-2263.
Andrieu S, Guyonnet S, Coley N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377-389.
Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388(10046):797-805.
Tom S, Mehta A, Izard S, et al. Life course socioeconomic status and later life Alzheimer's disease-related neuropathological lesions. Innov Aging. 2020;4(suppl 1):164. doi: 10.1093/geroni/igaa057.532
World Health Organization. Tackling NCDs: “best Buys” and Other Recommended Interventions for the Prevention and Control of Noncommunicable Diseases. Geneva: World Health Organization; 2017. https://apps.who.int/iris/handle/10665/259232
Ogilvie D, Adams J, Bauman A, et al. Using natural experimental studies to guide public health action: turning the evidence-based medicine paradigm on its head. J Epidemiol Community Health. 2020;74(2):203. doi: 10.1136/jech-2019-213085
The Academy of Medical Sciences. Improving the Health of the Public by 2040; 2016.
Lacy-Nichols J, Marten R, Crosbie E, Moodie R. The public health playbook: ideas for challenging the corporate playbook. Lancet Glob Health. 2022;10(7):e1067-e1072. doi: 10.1016/S2214-109X(22)00185-1

Auteurs

Sebastian Walsh (S)

Cambridge Public Health, University of Cambridge, Cambridge, UK.

Ishtar Govia (I)

Epidemiology Research Unit, Caribbean Institute for Health Research, The University of the West Indies, Mona Campus, Kingston, Jamaica.

Ruth Peters (R)

UNSW Ageing Futures Institute, University of New South Wales, Sydney, New South Wales, Australia.

Edo Richard (E)

Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands.
Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Blossom C M Stephan (BCM)

Institute of Mental Health, Jubilee Campus, University of Nottingham Innovation Park, Nottingham, UK.

Nikki-Anne Wilson (NA)

UNSW Ageing Futures Institute, University of New South Wales, Sydney, New South Wales, Australia.
Neuroscience Research Australia, Randwick, New South Wales, Australia.

Lindsay Wallace (L)

Cambridge Public Health, University of Cambridge, Cambridge, UK.

Kaarin J Anstey (KJ)

UNSW Ageing Futures Institute, University of New South Wales, Sydney, New South Wales, Australia.
Neuroscience Research Australia, Randwick, New South Wales, Australia.

Carol Brayne (C)

Cambridge Public Health, University of Cambridge, Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH